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Background: Cardiovascular disease (CVD) risk assessment is a critical step in the current 
approach to the primary prevention of CVD, particularly in low-income countries such as 
Burkina Faso. In this study, we aimed to assess the geographic and sociodemographic 
disparities of the ten-year cardiovascular risk in Burkina Faso.
Methods: We conducted a secondary analysis of the data from the first nationwide survey 
using the World Health Organization (WHO) STEPwise approach. Ten-year cardiovascular 
risk was determined using the WHO 2019 updated risk chart (WHO risk) as main outcome, 
and the Framingham risk score (FRS) and the Globorisk chart for secondary outcomes. We 
performed a modified Poisson regression model using a generalized estimating equation to 
examine the association between CVD risk and sociodemographic characteristics.
Results: A total of 3081 participants aged 30 to 64 years were included in this analysis. The 
overall age and sex-standardized mean of absolute ten-year cardiovascular risk assessed 
using the WHO risk chart was 2.5% (95% CI: 2.4–2.6), ranging from 2.3% (95% CI: 2.2– 
2.4) in Centre Est to 3.0% (95% CI: 2.8–3.2) in the Centre region. It was 4.6% (95% CI: 4.4– 
4.8) for FRS and 4.0% (95% CI: 3.8–4.1) for Globorisk. Regarding categorized CVD risk 
(absolute risk ≥10%), we found out that the age and sex-standardized prevalence of elevated 
risk was 1.7% (95% CI: 1.3–2.1) for WHO risk, 10.4% (95% CI: 9.6–11.2) for FRS, and 
5.9% (95% CI: 5.1–6.6) for Globorisk. For all of the three risk scores, elevated CVD risk 
was associated with increasing age, men, higher education, urban residence, and health 
region (Centre).
Conclusion: We found sociodemographic and geographic inequalities in the ten-year CVD 
risk in Burkina Faso regardless of risk score used. Therefore, population-wide interventions 
are needed to improve detection and management of adult in the higher CVD risk groups in 
Burkina Faso.
Keywords: geographic disparities, sociodemographic disparities, ten-year cardiovascular 
risk, Burkina Faso
Introduction
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality 
across the world.1 In 2015, about 17.9 million deaths were attributed to CVD 
worldwide, with 422.7 million cases of CVD.1 More than 80% of CVD-related 
deaths occur in low- and middle-income countries.2 The fatal complications of 
CVD are observed with older age but the pathological process starts early, in the 
young adult period. This pathological process is asymptomatic and is influenced by 
traditional cardiovascular behavior risk factors, such as tobacco use, alcohol use, 
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unhealthy diet, physical inactivity, and metabolic (inter-
mediate) risk factors such as hypertension, dyslipidemia, 
elevated blood glucose, and obesity.3,4 Behavioral and 
metabolic CVD risk factors often coexist in the same 
individual and synergistically increase the risk of future 
CVD.3 To address this issue, CVD-specific interventions 
are needed in all parts of health systems, and particularly 
at the primary care level.4 In low-resource settings, indi-
viduals or subgroups at high risk of CVD need to be 
identified early in order to apply cost-effective 
interventions.5–8 Two strategies are applicable to achieve 
this goal: the use of a single-risk-factor management strat-
egy, which focuses on one condition at a time (risk-factor 
approach), and the use of a more holistic approach con-
sidering several risk factors through an absolute CVD risk 
assessment (risk stratification approach).9 The cost- 
effective interventions based on each of these approaches 
are discussed in the literature.5,8,9 Recent studies in low- 
resource settings have shown the benefits of the absolute 
CVD risk approach.5,9 Risk assessment is a crucial step in 
the current approach to the primary prevention of athero-
sclerotic CVD, particularly in low-income countries such 
as Burkina Faso.10 As stated in many international guide-
lines, the current approach to the primary prevention of 
CVD is based on absolute risk assessment.4,11–13
Many CVD risk prediction tools to identify individuals 
or groups at high risk are available.14 Most of these risk- 
prediction tools were developed in high-income 
countries.15 No Sub-Saharan Africa (SSA) country has 
a specific CVD risk tool yet. However, some risk charts 
have been recalibrated for low-resource settings, including 
for use in SSA. Some of these risk charts have been used 
in some African countries and have produced divergent 
results regarding high risk of CVD. Studies have been 
conducted in four countries in SSA using the 
Framingham risk score (FRS), including Tunisia,16 
Ghana,17 South Africa,18 and Kenya,19 reporting various 
proportions of individuals at high risk, ranging from 2.9% 
in Kenya to 18.1% in Tunisia. Using the World Health 
Organization/International Society of Hypertension 
(WHO/ISH) risk chart, the prevalence of high CVD risk 
was found to be 4.5% in Angola,20 1.7% in Kenya,21 4% 
in Mozambique,22 and 14.9% in Nigeria.23 The variability 
in reported CVD risk according to the equation used and 
the study population create challenges for determining the 
actual prevalence of high CVD risk among the population 
in SSA, and has motived many calls for context-specific 
risk-score development.24 The development of a context- 
specific score requires substantial long-term cohort data, 
which are unavailable, expensive, or difficult to collect in 
low-resource settings.17–19,24,25 However, due to the lim-
itations of existing CVD risk prediction charts and the 
fundamental role of the current approaches in the primary 
prevention of CVD, many efforts have been expended to 
improve existing CVD risk assessment tools.25 In 2019, 
the WHO CVD Risk Chart Working Group updated the 
WHO/ISH risk prediction chart, recalibrating it for 21 
global regions and 79 countries, including Burkina 
Faso,26 using the WHO STEPwise survey, which offered 
a new opportunity to assess the CVD risk in low-resource 
settings. This risk chart (called WHO 2019 updated risk 
chart (WHO risk)) has been used to estimate population- 
wide distribution of CVD risk in China27 and Bangladesh.9 
Recently, Peiris et al28 have used WHO risk to estimate the 
10-year cardiovascular risk in 45 low and middle income 
countries including 18 countries of Africa. This study had 
found out that the CVD risk tended to be lower in sub- 
Saharan Africa compared with other world regions. To 
apply cost-effective preventative CVD interventions, it is 
essential to provide reliable information on the distribution 
of the population at high, intermediate, or low CVD risk.26 
All risk scores have limitations; to better understand the 
population distribution of CVD risk, different risk charts 
may be used (as Geldsetze et al29 did in India in 2019) 
since some charts provide complementary information.29
In Burkina Faso, CVDs are a major public health 
concern, placing an additional burden on the health system 
given the persistence of high-prevalence infectious dis-
eases. The health system in many low-income countries, 
including Burkina Faso, is not adapted to manage 
CVD,30,31 and CVD risk is poorly screened in primary 
care.32 High prevalences of some CVD risk factors 
(hypertension, diabetes, and tobacco use) have been 
reported.33–35 Given the high prevalence of these CVD 
risk factors, atherosclerotic CVD might be the most impor-
tant public health concern.36 Despite the importance of 
CVD risk to inform policymakers and health authorities 
in understanding the magnitude of the future distribution 
of CVDs in the population, no study has evaluated this 
score at the population-wide level in Burkina Faso. The 
country is currently experiencing demographic and epide-
miological transitions, which influence sociodemographic 
structure and the distribution of disease.37 The availability 
of the STEPwise survey with biochemical data at the 
nationwide level has offered an opportunity to assess the 
population-based CVD risk in the adult population in 
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Burkina Faso. The aim of this study was to evaluate the 
geographic and sociodemographic distribution of the ten- 
year CVD risk in Burkina Faso. To better understand the 
distribution of this risk in Burkina Faso, we assessed the 
ten-year CVD risk using three different risk scores: WHO 
risk, Framingham risk score (FRS), and Globorisk. The 
FRS is one of the most-used risk scores worldwide,17,38–40 
particularly in Africa,16,41 as it includes a large number of 
CVDs as endpoint events. In Burkina Faso, the FRS is the 
risk score most commonly used to estimate the ten-year 
cardiovascular risk in clinical practice.42,43 The Globorisk 
was specially developed for low-income countries and 
provides 182 country-specific risk charts, including one 
for Burkina Faso.44
Materials and Methods
Study Type and Population
We performed a secondary analysis of data from the first 
nationwide cross-sectional survey on noncommunicable 
disease risk factors in Burkina Faso (WHO STEPwise 
survey). In our study, we included data from the adult 
population aged from 30 to 64 years for FRS, WHO risk, 
and Globorisk. Those participants who reported a history 
of heart attack, chest pain from heart disease (angina), or 
stroke were excluded, as were those who were taking 
drugs to prevent or treat heart disease.
Data Source: WHO STEPwise Survey
The WHO STEPwise approach was used in 2013 to con-
duct the first nationwide survey on noncommunicable dis-
ease risk factors in Burkina Faso.45 The methodology of 
this survey is explained elsewhere.33–35 This survey was 
representative at the national and regional levels. Briefly, 
participants were randomly selected using a cluster- 
stratified three-stage sampling procedure. At the first 
stage, a total of 240 enumeration areas (EA) were selected 
and 20 households were selected from each EA (second 
stage). In the third stage, one adult aged from 25 to 64 
years was selected using the Kish method in each house-
hold. A total of 4800 adults were selected, of which 4695 
agreed to participate to the study. Two hundred (200) with 
history of CVD and 1260 participants with less than 30 
years old were not considered in the analysis (see flow 
chart: Figure 1). Information about eight risk factors was 
collected (hypertension, diabetes, hypercholesterolemia, 
obesity, tobacco use, alcohol consumption, low fruit and 
legume consumption, and low physical activity). Each risk 
factor was collected and recoded according to the WHO 
STEPwise approach guidelines.33,34,45 During the STEP 
survey, three measurements of blood pressure were done 
for each participant. The mean of last two measurements 
was used to define hypertension. The weight and height 
were measured using standard tool. These two anthropo-
metric parameters were used to define obesity. The blood 
glucose and cholesterol were measured from a whole 
blood sample obtained from a finger pick after 
a minimum of eight hours fasting. Informations about 
tobacco use, alcohol consumption, fruit and legume con-
sumption and physical activity were collected during face- 
to-face interviews using a WHO standardized 
questionnaire.
Outcome Variables
To assess the ten-year CVD risk, we used three risk scores: 
WHO risk, the FRS,15 and the Globorisk chart.44 These 
three risk scores provided complementary information 
about CVD risk among the adult population in Burkina 
Faso, as shown in Table 1. The WHO risk and Globorisk 
were specially developed for low-income countries. All 
the above scores perform well in discriminating persons 
who will develop CVD from those who will not.29
The WHO risk is the most recent risk chart available to 
assess the absolute ten-year CVD risk for people in low 
income countries. Six variables were used to estimate 
WHO risk.26 This risk chart was developed to assess ten- 
year cardiovascular risk for people aged from 40 to 80 
years and calibrated for 21 world regions using data from 
79 countries, including Burkina Faso. In this chart, risk is 
stratified into five groups: <5%, 5% to <10%, 10% to 
<20%, 20% to <30%, and ≥30%. For our analysis, we 
used the risk chart adapted to western SSA26 
(Supplemental Figure 1) to assign to each study participant 
their absolute WHO risk considering the level of each risk 
factor presented in the Supplementary Materials: 
Supplemental Table 2.
The 2008 FRS has been adapted for used in diverse 
populations around the world (Table 1).15 it was developed 
to assess ten-year cardiovascular risk for people aged from 
30 to 74 years. In our study, blood cholesterol was mea-
sured for each participant, offering an opportunity to use 
the laboratory FRS. The detailed process for computing 
individual absolute risk using FRS15 is described in the 
supplementary materials (Supplemental Table 1.). The 
FRS classifies participants into three groups: low, 
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moderate, or high risk, corresponding to <10%, 10–20%, 
and ≥20%, respectively.
The 2017 Globorisk44 was developed to assess ten-year 
cardiovascular risk for people aged from 40 to 74 years for 
182 countries, including Burkina Faso. The risk is strati-
fied into seven groups (<5%, 5% to 9%, 10% to 19%, 20% 
to 29%, 30% to 39%, 40% to 49%, and ≥50%). We used 
the risk chart for Burkina Faso (http://www.globorisk.org/ 
risk-charts) (Supplemental Figure 2) to assign an absolute 
individual CVD risk for each participant considering the 
input variables level (Supplemental Table 2). More details 
on the absolute risk calculation and a summary of the 
variables used to build the ten-year CVD risks are 
presented in the supplementary materials. To make consis-
tency between three equations, for Globorisk and WHO 
risk, we assigned the risk levels of participants aged 40 to 
44 years to participants aged 30 to 39 years, considering 
the levels of the input variables as done in previous 
studies.27,29,46 We then carried out sensitivity analysis for 
participants aged 40–64 years.
For each score, the absolute individual ten-year CVD 
risk was categorized as either low risk (<10%) or elevated 
risk (≥10%). The threshold at which an intervention 
should be introduced to prevent CVD as proposed by the 
WHO differs between countries.4,47,48 Using numerous 
risk scores, including FRS for CVD, and comparing 
Figure 1 Flow chart of study participants.
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different thresholds (5%, 10%, and 20%), a previous study 
showed that at the 10% threshold, the FRS has higher 
sensitivity and specificity.47 The most recent WHO guide-
lines include lifestyle change strategies and a 3 to 6 month 
follow-up for the population with an absolute CVD risk 
≥10%.49
Explanatory Variables
The main explanatory variables were residence (urban or 
rural), marital status (unmarried or married), education 
level (none, primary, secondary, or higher), occupation 
status (paid worker or jobless), and health region. The 
analyses were stratified by sex because of the well- 
known sex difference in CVD risk.29
Statistical Analysis
In the first part of our study, we calculated and pre-
sented the absolute ten-year CVD risk in the initial 
categorization and the variability of the mean absolute 
CVD risk. We then used the dichotomized CVD risk 
(low and elevated risk) to estimate the prevalence of 
elevated risk by sociodemographic characteristics and 
health region (map). To correct the prevalence for age– 
sex variation between sample and national population, 
we standardized the prevalence of elevated risk using 
the age and sex structure of the adult population in 
Burkina Faso in 2013.50 To examine the association 
between the sociodemographic characteristics and ele-
vated risk, we performed a modified Poisson regression 
model using a generalized estimating equation. With 
this model, we have considered clustering of the obser-
vations and we derived prevalence ratios (PRs) and 
95% confidence interval. All maps were plotted using 




A total of 3081 participants (1533 women and 1548 
men) aged 30 to 64 years including 1735 participants 
aged 40 to 64 years (818 women and 917 men) from 13 
health regions were included in our analysis (Figure 1). 
Table 2 shows the sociodemographic characteristics of 
the study participants by sex. The majority of women 
(75.1%) and men (80.0%) were living in rural areas. 
Regarding education level, 75.9% of men and 83.8% 
of women aged from 30 to 64 years had not attended 
a formal school. Table 3 shows the characteristics of 
participants with and without elevated risk as defined by 
WHO risk. These characteristics for FRS and Globorisk 
are presented in supplementary materials (see 
Supplemental Tables 4 and 8).
Cardiovascular Risk at National and 
Regional Level
The overall age and sex-standardized mean of ten-year 
cardiovascular risk was 2.5% (95% CI: 2.4–2.6) for 
WHO risk. Regarding the mean of WHO risk, we 
found geographic disparities which showed that the age 
and sex-standardized means of ten-year cardiovascular 
Table 1 Population, Input Variables, and Outcome of Each Ten-Year CVD Risk Score
CVD Risk 
Score





Aged 40 to 80 years, data from 85 
prospective cohorts in the Emerging Risk 
Factors Collaboration, recalibrated using 
data from 79 countries collected with the 
WHO STEPwise Approach to Surveillance
Age, sex, smoking status, diabetes, 
systolic blood pressure, treatment 
for hypertension, history of diabetes, 
total cholesterol
Myocardial infarction, fatal coronary heart 
disease, or stroke event
FRS for CVD 
200815
Aged 30 to 74 years, Framingham cohort Age, sex, smoking status, diabetes, 
systolic blood pressure, treatment 
for hypertension, total cholesterol, 
HDL cholesterol
Coronary death, myocardial infarction, 
coronary insufficiency, angina ischemic stroke, 
hemorrhagic stoke, and transient ischemic 




Aged 40 to 74 years, eight prospective 
cohorts and recalibrated for 182 countries
Age, sex, smoking status, diabetes, 
blood pressure, and total cholesterol
Fatal and nonfatal myocardial infarction and 
stroke and sudden cardiac death
Abbreviations: CVD, cardiovascular disease;FRS, Framingham risk score; WHO, World Health organization; HDL, high-density lipoprotein.
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risk assessed using WHO risk ranged from 2.3% (95% 
CI: 2.2–2.4) in the Centre Est region to 3.0% (95% CI: 
2.8–3.2) in the Centre region. The overall age and sex- 
standardized mean of ten-year cardiovascular risk was 
4.6% (95% CI: 4.4–4.8) for FRS, ranged from 3.9% 
(95% CI: 3.4–4.3) in Sud Ouest to 6.0% (95% CI: 5.5– 
6.6) in the Centre region. It was 4.0% (95% CI: 3.8–4.1) 
for Globorisk and ranged from 3.4% (95% CI: 3.3–3.7) 
in Centre Est to 5.0% (95% CI: 4.6–5.5) in Centre. As 
shown in Figure 2, the age and sex-standardized mean of 
absolute risk (using WHO risk) was higher in the Centre 
region (Ouagadougou). The same results were reported 
when use FRS (Supplemental Figure 3) and Globorisk 
(Supplemental Figure 4)
As shown in Figure 3, using WHO risk, 97.8% (95% 
CI: 96.7–98.5) of the study population had a risk of <10%, 
2.1% (95% CI: 1.4–3.2) had arisk of 10% to <20%, and 
0.1% (95% CI: 0.0–0.3) had a a risk of ≥20%. Using FRS, 
87.7% (95% CI: 86.1–89.1) of the study population had an 
absolute risk of <10%, 9.4% (95% CI: 8.2–10.6) had a risk 












Age (years) (mean ± 
SD)
41.9 ± 9.47 43.7±9.93
Age (years)
30–39 715 (46.6) 631 (40.8) 1346 (43.7)
40–49 440 (28.7) 459 (29.7) 899 (29.2)
50–59 285 (18.6) 304 (19.6) 589 (19.1)
≥60 93 (6.1) 154 (9.9) 247 (8.0)
Education
Unschooled 1284 (83.8) 1171 (75.9) 2461 (79.9)
Primary 170 (11.1) 259 (16.8) 429 (13.9)
Secondary and 
higher
79 (5.2) 112 (7.3) 191 (6.2)
Marital status
Single 223 (14.6) 175 (11.4) 401 (13.0)
Married 1310 (85.4) 1370 (88.7) 2680 (87.0)
Residence
Urban 381 (24.8) 310 (20.0) 691 (22.4)
Rural 1152 (75.1) 1238 (80.0) 2390 (77.6)
Occupational status
Paid worker 872 (57.0) 1494 (96.6) 2366 (76.8)
Jobless 657 (43.0) 53 (3.4) 715 (23.2)
Region
Cascades 45 (2.9) 53 (3.4) 98 (3.2)
Boucle du Mouhoun 119 (7.8) 177 (11.4) 296 (9.6)
Centre 209 (13.6) 168 (10.8) 377 (12.2)
Centre-Est 149 (9.7) 135 (8.7) 284 (9.2)
Centre-Nord 131 (8.6) 137 (8.9) 268 (8.7)
Centre-Ouest 148 (9.7) 118 (7.6) 266 (8.6)
Centre-Sud 86 (5.6) 89 (5.7) 175 (5.7)
Est 96 (6.3) 158 (10.2) 254 (8.2)
Hauts-Bassins 157 (10.2) 163 (10.5) 320 (10.4)
Nord 119 (7.8) 123 (7.9) 242 (7.8)
Plateau Central 124 (8.1) 57 (3.7) 181 (5.9)
Sahel 71 (4.6) 97 (6.3) 168 (5.4)
Sud-Ouest 79 (5.2) 73 (4.7) 152 (4.9)
Table 3 Elevated Risk of Ten-Year Cardiovascular Event (WHO 













n (%) n (%) n (%) n (%)
All participants 1519 14 1495 53
Age (years)
30–39 715 (46.3) 0 (0.0) 628 (41.4) 3 (3.4)
40–49 440 (29.8) 0 (0.0) 456 (33.0) 3 (5.8)
50–59 282 (18.9) 3 (20.3) 291 (18.5) 13 (22.4)
≥60 82 (5.0) 11 (79.7) 120 (7.1) 34 (68.5)
Education
Unschooled 1275 (84.1) 9 (67.8) 1136 (76.0) 41 (76.9)
Primary 168 (11.2) 2 (19.7) 252 (16.2) 7 (11.9)
Secondary and 
sup
76 (4.7) 3 (12.5) 107 (7.8) 5 (11.3)
Marital status
Single 219 (13.0) 4 (29.4) 173 (10.2) 5 (5.2)
Married 1300 (87.0) 10 (70.6) 1322 (89.8) 48 (94.8)
Residence
Urban 373 (29.4) 8 (74.3) 297 (24.3) 13 (33.3)
Rural 1146 (70.6) 6 (25.7) 1198 (75.7) 40 (66.7)
Occupational 
status
Paid worker 868 (54.5) 4 (18.8) 1447 (97.1) 47 (81.3)
Jobless 651 (45.5) 10 (81.2) 48 (2.9) 6 (18.7)
Notes: aWeighted percentage. 
Abbreviation: WHO risk, World health organization 2019 updated risk chart.
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Figure 2 Age and sex standardized mean of absolute cardiovascular risk (left) and prevalence of elevated risk (WHO risk≥10%) (right) by region. The mean of 
absolute cardiovascular risk was significantly higher in Centre region (p<0.001). The prevalence of elevated risk was also higher in Centre region followed by Haut 
Bassins (p<0.001).
Figure 3 Weighted prevalence of low, moderate and high 10-years risk of cardiovascular disease assessed using WHO 2019 updated risk, Framingham risk score and 
Globorisk chart. (These values were not standardized).
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of 10% to <20%, and 2.9% (95% CI: 2.3–3.8) had a risk of 
≥20%. The proportions when using Globorisk were 92.9% 
(95% CI: 91.4–94.1) for <10%, 6.0% (95% CI: 4.9–7.2) 
for 10% to <20%, and 1.2% (95% CI: 0.8–1.8) for ≥20%.
The overall age and sex-standardized prevalence of 
elevated risk was 1.7% (95% CI: 1.3–2.1) for WHO 
risk (In a sensitivity analysis, this prevalence was 
(2.9% (95% CI: 2.2–3.6) when excluded adult under 
40 years of age), varied between 0.7% (95% CI: 0.0– 
1.9) in Centre Est to 4.5% (95% CI: 2.2–5.7) in Centre. 
Using FRS, this prevalence was 10.4% (95% CI: 9.6– 
11.2), ranged from 6.4% (95% CI: 4.0–8.7) in Centre 
Sud to 16.5% (95% CI: 13.6–19.4) in Centre. Using 
Globorisk, we found that the age and sex- 
standardized prevalence of elevated CVD risk was 
5.9% (95% CI: 5.1–6.6) (In a sensitivity analysis, this 
prevalence was 10.6% (95% CI: 9.3–11.9) when 
excluded adult under 40 years of age), and ranged 
from 3.5% (95% CI: 1.1–5.2) in Est to 12.5% (95% 
CI: 8.8–14.6) in Centre. All three equations showed 
a higher prevalence of elevated risk in the Centre 
region, which is the capital of the country (main 
urban area) (see Figure 2 and Supplemental Figures 3 
and 4).
Sociodemographic Disparities of Ten-Year 
Cardiovascular Risk
The means of absolute CVD risk by sociodemographic 
characteristics are presented in the supplementary materi-
als (Supplemental Tables 3, 7 and 11). Table 4 shows the 
age and sex-standardized prevalence of elevated risk by 
sociodemographic characteristics using WHO risk: 2.6% 
(95% CI: 1.9–3.3) for men and 0.9% (95% CI: 0.5–1.4) for 
women (p-value of difference <0.001). The overall age 
and sex-standardized prevalence was 3.1% (95% CI: 1.9– 
4.3) in urban areas and 1.4% (95% CI: 1.0–1.8) in rural 
areas (p = 0.003). Among men, the age-standardized pre-
valence of elevated risk was 3.5% (95% CI: 1.6–5.4) in 
urban areas and 2.4% (95% CI: 1.7–3.1) in rural areas (p = 
0.27). Among women, it was 2.7% [95% CI: 1.1–4.4) and 
0.5% (95% CI: 0.1–0.9) in urban and rural areas, respec-
tively (p<0.001). The age and sex-standardized prevalence 
of elevated risk increased with education level. The overall 
age and sex standardized prevalence of elevated risk 
Table 4 Age- and Sex-Standardized Prevalence Elevated Ten-Year Risk of Cardiovascular Event (WHO Risk ≥10%) by 
Sociodemographic Characteristics
Characteristics Mena Womena Totalb
All participants 2.6 [1.9–3.3] 0.9 [0.5–1.4] 1.7 [1.3–2.1]
Age (years)
30–39 0.3 [0.1–1.0] 0 0.2 [0.0–0.4]
40–49 0.6 [0.2–2.1] 0 0.3 [0.0–0.6]
50–59 4.2 [2.4–7.1] 1.1 [0.3–4.3] 2.5 [1.3–3.7]
≥60 26.1 [16.8–38.1] 14.1 [7.6–24.7] 16.3 [11.7–21.0]
Education
Unschooled 2.4 [1.7–3.1] 0.7 [0.2–1.1] 1.4 [1.0–1.8]
Primary 3.0 [0.9–5.0] 2.6 [0.0–6.0] 2.8 [0.7–4.8]
Secondary and sup 7.6 [2.6–12.5] 8.0 [4.7–11.3] 7.8 [4.9–10.6]
Marital status
Single 3.0 [0.5–5.4] 0.6 [0.0–1.2] 1.7 [0.5–2.8]
Married 2.6 [1.9–3.3] 2.0 [0.4–1.8] 1.8 [1.3–2.2]
Residence
Urban 3.5 [1.6–5.4] 2.7 [1.1–4.4] 3.1 [1.9–4.3]
Rural 2.4 [1.7–3.1] 0.5 [0.1–0.9] 1.4 [1.0–1.8]
Occupational status
Paid worker 2.5 [1.8–3.2] 0.5 [0.0–1.1] 1.4 [1.0–1.9]
Jobless 4.3 [0.0–8.9] 1.4 [0.6–2.1] 2.7 [0.6–4.8]
Notes: aStandardized by age only; bStandardized by age and sex. 
Abbreviation: WHO risk, WHO 2019 updated risk chart.
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among the study population who had achieved secondary 
school education was 7.8% (95% CI: 4.9–10.6) versus 
2.8% (95% CI: 0.7–4.8) for those who achieved primary 
school and 1.4% (95% CI: 1.0–1.8) for those who did not 
attend formal education (p < 0.001). Among men, the age- 
standardized prevalence of elevated risk was 7.6% (95% 
CI: 2.6–12.5) for those who had completed secondary 
school, 3.0% (95% CI: 0.9–5.9) for those who completed 
primary, and 2.4% (95% CI: 1.7–3.1) for those who did 
not attend formal schooling (p < 0.001). Among women, 
the age-standardized prevalence was 8.0% (95% CI: 4.7– 
11.3) for those with a secondary school education, 2.6% 
(95% CI: 0.0–6.0) for those with primary education, and 
0.7% (95% CI: 0.2–1.1) for those who had not attended 
formal schooling (p < 0.001). We also found age, sex, 
residence, and education level disparities of age- 
standardized prevalence of elevated risk when using FRS 
or Globorisk (see Supplemental Tables 5 and 9).
Table 5 shows the association between elevated CVD 
risk assessed using the WHO risk and sociodemographic 
characteristics after multivariate analysis. Men had 
a higher ten-year CVD risk compared to women (adjusted 
prevalence ratio (aPR):3.04 [95% CI: 1.52–6.05], p < 
0.001). The result was the same when we used FRS and 
Globorisk (see Supplemental Tables 6 and 10). The pre-
valence of elevated risk increased with age. Adjusting for 
all variables in Table 2, high levels of education was 
significantly associated with an elevated risk. As shown 
in Table 5, the prevalence of elevated risk was 3.17 times 
(aPR: 3.17, 95% CI: 1.30–7.72) higher among individuals 
who finished secondary school than those who were 
unschooled. The residence location was not significantly 
associated with elevated risk when adjusted for all expla-
natory variables (sex, age, marital status, education and 
occupation status) in FRS and Globorisk (see 
Supplemental Tables 6 and 10). However, the rural resi-
dents showed lower prevalence of elevated risk compared 
to urban residents using all three risk scores.
Discussion
To the best of our knowledge, this analysis represents the 
first nationwide estimation of CVD risk in Burkina Faso. It 
is also one of the first population-based sociodemographic 
and geographic assessment of disparities in the ten-year 
CVD risk in western SSA using the new WHO risk chart. 
The findings show strong individual-level sociodemo-
graphic and geographic disparities. These disparities were 
similar across the risk scores used in this study. In 2018 in 
Table 5 Factors Associated with Elevated WHO Risk (WHO Risk ≥10%) Using Multivariate Modified Poisson Regression with GEE 
Model
cPR [95% CI] p -value aPR [95% CI] p -value
Sex <0.001 0.001
Women Ref. Ref.
Men 4.14 [2.23–7.70] 3.04 [1.52–6.05]
Age (per ten years) 6.75 [4.33–10.35] <0.001 5.56 [3.94–7.84] <0.001
Education 0.25 0.030
Unschooled Ref. Ref.
Primary 1.03 [0.50–2.11] 1.53 [0.74–3.18]
Secondary and above 1.93 [0.87–4.26] 3.17 [1.30–7.72]
Marital status 0.92 0.92
Single Ref. Ref.
Married 1.03 [0.50–2.14] 1.03 [0.49–2.17]
Residence 0.12 0.37
Urban Ref. Ref.
Rural 0.63 [0.35–1.12] 0.75 [0.41–1.40]
Occupational status 0.74 0.32
Paid worker Ref. Ref.
Jobless 0.90 [0.49–1.65] 1.40 [0.71–2.78]
Abbreviations: cPR, crude prevalence ratio; aPR, adjusted prevalence ratio, outcome variable is the high risk (WHO risk ≥ 10%); CI, confidence interval; Ref, reference; 
GEE, general estimating equation; WHO risk, WHO 2019 updated risk chart.
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India, Geldsetze et al29 also reported similarities in the 
distribution of CVD risk, even though they used different 
scores, which suggests that despite the limitation of each 
CVD risk score, there are some sociodemographic char-
acteristics and location that indicate a higher risk of CVD 
within ten years. As recommended by the WHO, these 
groups require substantial individual lifestyle change stra-
tegies to reduce the future incidence of CVD.49 As high-
lighted by Geldsetze et al,29 the clinical endpoint events 
might explain the higher prevalence of elevated risk 
reported using FRS compared to WHO risk and 
Globorisk in our study. Thus, FRS included a large number 
of CVD as endpoint events to derive the equation com-
pared to WHO risk and Globorisk (see Table 1).
We report an age and sex-standardized prevalence of 
elevated risk of 1.7% using WHO risk, even when choos-
ing a low threshold (WHO risk ≥10%). This prevalence 
seems to be lower than that reported in Bangladesh. 
A study conducted in Bangladesh in 2020 found that 
14.9% of the study population had a WHO risk of 
≥10%.9 In a recent study, Peiris et al28 have shown that 
the median of CVD risk seem to be lower in SSA com-
pared with other world regions. Nonetheless, previous 
study using the older version of the WHO risk reported 
a prevalence of 23.1% (WHO/ISH ≥10%) among workers 
at the local level in Nigeria.53 When considering other risk 
scores such as FRS, our reported prevalence is lower than 
those reported in other studies in Africa. Using FRS, we 
found a prevalence of 10.4% for elevated risk. In a study 
conducted in a similar context (Ghana), Boateng et al17 
found that 33.8% (if using FRS ≥ 10%) of the study 
population were predicted to be at high ten-year CVD 
risk (calculated using FRS among people aged 40 to 70 
years old). The age group used in the work of Boateng 
et al17 and the present study might explain this difference. 
However, CVD risk differs widely with the equation used, 
partly due to the components of clinical endpoints pre-
dicted and the study population.47 Our lower estimated 
CVD risk contrasts with the high CVD incidence and 
CVD mortality found in the country compared to most 
countries worldwide.54,55 A previous study carried out in 
Burkina Faso reported a heavy burden of noncommunic-
able disease, including CVD, with 17.9% of the adult 
population presenting with angina pectoris.31 This contrast 
is due to the lower capacity of health system to detect and 
treat people with elevated risk before the CVD occur. 
There is an urgent need for policymakers to strengthen 
the health system of Burkina Faso to prevent and manage 
CVD, particularly among people at elevated risk of 
CVD.56 Additionally, our findings suggest that 
a substantial proportion of the population needs interven-
tion to prevent CVD. Therefore, the health system must be 
strengthened to screen and treat people at high risk of 
CVD to prevent CVD.
Our results confirm the higher ten-year CVD risk 
among men compared to women, as reported by Saidi 
et al16 in Tunisia (2015), Gaziano et al18 in South Africa 
(2013), Geldsetze et al29 in India (2018) and recently 
Peiris et al28 (2021). All three equations identified sex 
disparities in the ten-year CVD risk and a higher risk in 
men compared to women. Men adopt many combined risk 
behaviors that increase the risk of CVD.3 The education 
level disparities reported in our analysis confirm those 
reported in many previous studies.16,18,29,57 As found by 
Geldsetze et al,29 the prevalence of an elevated risk of 
cardiovascular events tends to increase with education 
level, which was in line with our findings. This might be 
due to factors correlated with high education level such as 
high socioeconomic index, urbanity, low physical activity, 
and other lifestyle factors that increase the level of CVD 
risk. Peiris et al28 had found out that wealthier quintiles are 
associated with higher median CVD risk. In the same 
study Peiris et al28 had also noted that CVD risk is lower 
among people with primary or higher level of education. 
The independent association between education and CVD 
risk is still discussed in the literature. Most studies shown 
that the level of education is inversely associated with 
CVD incidence and mortality in low- and middle-income 
countries.58,59 As noted by Rosengren et al,59 this apparent 
paradox might be explained by inequality in access to 
cardiovascular health care, which is likely limited for 
people with low levels of education compared to those 
with high levels of education in low-income countries. 
Interventions to reduce the level of cardiovascular risk 
factors might be combined with strategies to improve 
cardiovascular healthcare accessibility to promote the sec-
ondary prevention of CVDs.
We found geographic disparities in the distribution of 
CVD risk in Burkina Faso. All three scores showed 
a higher prevalence of elevated risk of CVD in the 
Centre region (Ouagadougou). This tended to confirm the 
spatial clustering of ten-year cardiovascular risk described 
in the literature.16,29 Due to urbanization and changes in 
lifestyle, urban area is recognized as the hotspots of car-
diovascular diseases in many parts of the world.16,57,60,61 
The disparities between health regions in our analysis are 
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mostly due to differences in urbanization, changes in life-
style, and unbalanced socioeconomic development 
between the regions in Burkina Faso, since we standar-
dized the proportion of elevated risk by age and sex. To 
address CVD risk in the country, population-based life-
style modification strategies might be introduced among 
people with elevated risk because drug-based interventions 
are unaffordable for the majority of the population.4
Strengths and Limitations of the 
Study
The main limitation of the present study was the inability 
to exclude all participants with current or previous con-
firmed CVD, since clinical examinations were not per-
formed. However, we excluded participants who reported 
heart attack, angina, or stroke. We used equations that 
were developed for specific age groups (30 to 74 years 
for FRS, 40 to 80 years for WHO risk and 40 to 74 years 
for Globorisk) to assess the CVD risk for those aged 30 to 
64 years. This difference might have caused underestima-
tion of the prevalence of elevated risk compared to other 
studies in Africa (eg, Tunisia, South Africa, and Ghana). 
Furthermore, for WHO risk and Globorisk, we used a risk 
chart for people with 40–49 years to assign absolute risk 
for people with 30–39 years as previously done in others 
studies.27,29,46 However, this might overestimate the abso-
lute risk among people with 30–39 years since the risk 
increase with age. The correlation between the prediction 
and outcome remains uncertain and varies when the algo-
rithms are applied to populations that are not similar to 
those used to develop the system.62. Moreover, the sample 
size was low and might cause low precision of associa-
tions measured. Another limitation in this study is its 
cross-sectional nature. Then, we cannot exclude a risk of 
survival bias as participants with acute complications of 
CVD risk factors may die prematurely. There is residual 
confounding, since economic and cultural aspect of house-
hold were not collected. Furthermore, despite the use of 
the standard WHO measurement instruments, there was 
some potential measurement bias. Finally, we assessed the 
geographic distribution at the health region level, which is 
the level at which the STEPwise survey was designed to 
be representative. Therefore, local (subregional) hotspots 
might be masked and not highlighted in our study. Beyond 
these limitations, we provide for the first time useful find-
ings to understand the future distribution of CVDs related 
to a population-based data, which might be used to drive 
cost-effective population-wide preventive campaigns in 
Burkina Faso.
Conclusion
In this study, we reported for the first time the prevalence 
of elevated risk of ten-year CVD risk among the adult 
population in Burkina Faso. The analysis demonstrated 
geographic, sex, age, and education disparities in the dis-
tribution of the ten-years CVD risk in Burkina Faso. Our 
findings suggest a need to develop prevention and control 
strategies (eg tobacco control policy, promoting physical 
activity, air quality regulation particularly in urban area) to 
address CVD risk among vulnerable sociodemographic 
groups and geographic locations who represent a higher 
proportion of the population with elevated ten-year CVD 
risk.
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